On tonight's MAD MONEY show on CNBC, Cramer reviewed what the state of the stent market will be.
There is a meeting Thursday at the FDA where the FDA is going to make a recommendation or decision on stents and the approval of them. Cramer thinks that stents will stay and the FDA may either ask for more data or just make token comments.
Both Boston Scientific Corp. (NYSE:BSX) & Johnson & Johnson (NYSE:JNJ) have been down on the possibility that an FDA decision "could" go against them. Cramer said that BSX is the riskier of the two because it has more business leveraged, and JNJ has diversified mush of its operations. Cramer prefers BSX for a trade, but warned again that this has risks. BSX traded up almost 4% today to $16.56, but traded up another 0.9% to $16.70 after Cramer discussed this.
Cramer has a heart: says Boston Scientific best call in FDA stent decision
Posted Dec 5th 2006 6:12PM by Jon Ogg
Filed under: After the bell, Analyst reports, Johnson and Johnson (JNJ), Boston Scientific (BSX)
Biotech ETFs: Best bets on health care reform
Cramer on BloggingStocks: The world's been waiting for the new GM 
Dell fights Taiwanese authorities over pricing mishaps
Reader Comments (Page 1 of 1)
12-06-2006 @ 11:07AM
Dave said...
It's about time for both FDA & BSX to get off dead center on these issues. Here is a company[BSX]that can benifit from several sales tools. J & J has adjusted and continues to grow!!!
Now if a change of CEO can move this product line so be it.
Cramer just keeps things in proper perspective with BSX and our FDA. How long has this coated Stent issue been going on???
They really are under valued and God Bless Coated Stents.